<DOC>
	<DOCNO>NCT02896231</DOCNO>
	<brief_summary>This phase I , first-in-human dose-escalation study conduct determine maximum tolerate dose ( MTD ) , recommend phase II dose ( RP2D ) , dose-limiting toxicity ( DLTs ) , pharmacokinetics ( PK ) profile , preliminary antitumor activity PLB1001 .</brief_summary>
	<brief_title>First-in-human Phase I Study Selective c-Met Inhibitor PLB1001</brief_title>
	<detailed_description>This Phase I , open-label , multicentre study PB1001 administer orally patient Met-positive ( Met+ ) advance NSCLC . The study include Dose-escalation Part ( part A ) Dose Expansion Part ( part B ) . The aim part A estimate MTD identify dose limited toxicity ( DLT ) recommend phase II dose ( RP2D ) PLB1001 single agent well determine PK/PD profile .Once response observe certain dose level , follow expansion part ass clinical efficacy safety PLB1001 single agent . Aprox . 40 patient enrolled PART A , 20-30 patient expansion cohort . PLB1001 potent selective c-Met inhibitor . PLB1001 act cancer block abnormal cmet-mediated signalling , lead profound tumour growth inhibition xenograft non-small cell lung cancer ( NSCLC ) tumour . Preliminary data c-Met inhibitor INC 280 provide possibility safety clinical activity PLB1001 monotherapy patient population .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Signed Informed Consent Form Age≥18 year Histologically cytologically confirm advanced nonsmall cell lung cancer Must evidence cMet positivity result molecular prescreening evaluation At least one measurable lesion per RECIST v1.1 Patients must recover toxicity relate prior anticancer therapy grade ≤ 1 ECOG Performance Status 02 Previous current treatment cMet inhibitor HGFtargeting therapy Symptomatic central nervous system ( CNS ) metastases neurologically unstable require increase dos steroid control , patient CNS deficit . Clinically significant , uncontrolled heart disease . Unstable angina History document congestive heart failure ( New York Heart Association functional classification &gt; II ) Uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 145 mm Hg and/or Diastolic Blood Pressure ( DBP ) ≥ 85 mm Hg Arrhythmias Active peptic ulcer disease gastritis Adverse event prior anticancer therapy resolve Grade ≤ 1 , except alopecia Major surgery within 4 week prior start PLB1001 Previous anticancer investigational agent within 4 week first dose PLB1001 . If previous treatment monoclonal antibody , treatment must discontinue least 6 week first dose PLB1001 . Pregnant nursing woman Involved clinical trial &lt; 30 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>